Patients with prior stroke (PS) undergoing chronic dialysis are at a high risk of mortality. However, little is known about the cumulative risk and survival rate of dialysis patients with long-term follow up. The aim of this study was to assess risks for mortality between patients with and without PS undergoing chronic haemodialysis (HD).
Atherosclerosis is widely acknowledged to occur more frequently in patients with chronic kidney disease (CKD) 1 . Uremia per se is a cardiovascular risk factor independent of classic cardiovascular risk factors 2 . There is growing evidence of an association between CKD and adverse cardiovascular disease. Collins et al 3 reported that patients with CKD were associated with a two-fold increase in cardiovascular disease as compared with general population. The prevalence of stroke was higher among incident cases of end-stage renal disease (ESRD) compared with the general population 4 , and 7-14 per cent of ESRD patients had a prior history of stroke (PS) at the time of initiation of dialysis [5] [6] [7] [8] [9] .
These observations have an important public health and socio-economic impact. The prevalence of ESRD has increased markedly globally during the past few years, especially in Taiwan which has been ranked first in the world since 2002 10, 11 . Atherosclerotic cardiovascular disease is a major cause of morbidity 1 and mortality 8, 12 in patients with ESRD. Many studies have tried to identify the predictors for mortality in dialysis patients, with most focusing on risk factors, such as age, diabetic mellitus (DM), hypertension (HTN), heart failure (HF), coronary artery disease (CAD) and duration of follow up, etc 6, [13] [14] [15] . However, studies on PS and mortality among patients with dialysis are lacking. Some studies have reported on ischaemic stroke and dialysis, however, the results have been inconsistent. Herzog et al 12 reported that PS independently increased the risk of all-cause mortality in dialysis patients, while Lamping et al 5 did not find any significant association with PS 5 .
We hypothesize that PS is an important predictor for mortality and poor outcome in haemodialysis (HD) patients. We used data from the Taiwan National Health Insurance Research Database (NHIRD) 16 to investigate whether the PS was associated with an increased risk of all-cause mortality or poor long-term prognosis in patients with or without PS undergoing chronic haemodialysis.
Material & Methods
The National Health Insurance (NHI) programme, which provides compulsory universal health insurance, was implemented in Taiwan since 1995. With the exceptions of prison inmates, all citizens are enrolled in the programme. Patients with ESRD are eligible for any type of renal replacement therapy under the NHI programme without the need for extra payment 16 .
Patients in this study were drawn from NHIRD with trial registration number (NHRI-NHIRD-99182). In cooperation with NHI, a specific search was applied and all patients on dialysis with applying payment for dialysis from 1998 to 2008 in Taiwan were drawn. The NHIRD covers nearly all (>99%) inpatient and outpatient claims for approximately 23 million population of Taiwan. It is one of the largest and most comprehensive databases of its kind in the world, and had been used extensively in various studies 16, 17 . The NHIRD provides encrypted patient identification numbers, gender, date of birth, dates of admission and discharge, the medical institutions providing the services, the ICD-9-CM (International classification of diseases, ninth revision, Clinical modification) 18 codes of diagnoses (up to five) and procedures (up to five), and outcomes. Information from the NHIRD was considered appropriately for the derivation of accurate estimation of chronic diseases as ESRD and comorbidities. All NHIRD can be interlinked with each individual personal identification number.
Patient selection and definition:
A longitudinal cohort study was designed in dialysis patients. Adult patients (age ≥18 yr) of ESRD on maintenance HD (who initiated HD treatment between January 1, 1999, and December 31, 1999) were selected. Several studies have been published in Taiwan using NHIRD for mortality [19] [20] [21] [22] [23] . The Bureau of NHI issues major illness/ injury certificate to patients who suffer from ESRD on maintenance dialysis. We linked the major illness/injury certificate file to get the date of death. The enrolled subjects were followed up from the first reported HD session to the date of death, end of dialysis or December 31, 2008. Patients who underwent peritoneal dialysis (PD) or switched type of dialysis were excluded based on the standard rules 24 . A total of 5672 incident HD patients were analyzed in this study.
Ascertainment of demographic and co-morbid variables:
The diagnostic codes were linked through the outpatient and hospitalization claims databases of the NHI and were searched for the survival status, date of death, demographics and other relevant co-morbid variables. Co-morbidity was crucial for the survival rate and mortality, and all subjects were enrolled including those with PS, DM, HTN, HF, CAD, peripheral vascular disease (PVD), systemic lupus erythematous (SLE), liver cirrhosis (LC) and polycystic kidney disease (PCKD). The ICD-9-CM 18 codes were used to define each co-morbidity: 25 . The survival rate was estimated using the Kaplan-Meier method by PS and age-group (<55, ≥55 yr). The Cox`s proportional hazard model was used to identify the risk factors for mortality with covariates such as age, sex, DM, HTN, PS, HF, CAD, PVD, SLE, LC and PCKD, and a multivariate regression model estimating all-cause mortality with hazard ratios (HRs) and 95% confidence intervals (CI) was derived. Interaction terms between PS and the two age groups were also tested. Further analyses included stratifying patients on the basis of age-group. Table I shows the characteristics of the enrolled HD patients with and without PS. Among the eligible patients, 650 patients (11.5%) had PS compared to the majority of non-PS. There were substantial differences between between the two groups in numerous prognostic indicators of death, such as the proportion that were male (P<0.05), elderly (P<0.001), had a history of DM, HTN, HF, CAD, or PVD (P<0.001).
Results

Risk factors for all-cause mortality in 1999 incident HD patients:
The risks for all-cause mortality are listed in Table II . Using crude and multivariate analyses, sex, age, DM, HTN, HF, CAD, stroke, PVD, and LC were shown to have associations with mortality. The interaction between PS and different age groups was found to be statistically significant (P=0.005). Therefore, data were further analyzed stratified by different age groups (aged 18-54 and ≥55 yr). Table III shows the hazard ratios for all-cause mortality by age stratification (aged 18-54 and ≥55 yr). Male gender, DM, HF, CAD, PVD, LC and PS were associated with an increased risk of mortality. The patients with PS who were aged 18-54 yr had a 2.25-fold (HR 2.25, 95% CI: 1.73-2.93) increased risk of mortality, and those aged ≥55 had a 1.48-fold (HR 1.48, 95% CI: 1.31-1.66) increased risk of mortality compared to those without PS (P<0.001). After multivariate adjusted hazards ratios analyses, patients with PS were still at a higher risk of mortality than those without PS. The increased risk was 54 per cent (95% CI: 18%-102%) for patients aged 18-54 yr, and 34 per cent (95% CI: 18%-51%) in those aged ≥55 yr.
Cumulative survival rate:
The cumulative survival rate in patients without PS was 96 per cent at the first year, (Fig. a) , and the older patients had a worse survival rate. Further stratified by PS and different age groups, the younger patients (18-54 yr) without PS had the longest mean survival of up to 102.2 months (95% CI: 100.7-103.7), followed by the younger patients with PS of 85.8 months (95% CI: 78.8-92.9), the older (≥55 yr) patients without PS of 73.6 months (95% CI: 72.1-75.1), and the older patients with PS of 60.20 months (95% CI: 56.6-63.8), all of which were statistically significant (log-rank: P<0.001) (Fig. b) .
Discussion
We compared all-cause mortality between patients with and without PS among the registered HD population from the Taiwan NHIRD. After adjusting for age, gender and other covariates, PS was found to play an important role in mortality and poor outcome. The risk of mortality increased by 54 and 34 per cent in those aged 18-54 and ≥55 yr, respectively . No relevant data were found after a search of the literature, and we hypothesized that stroke type (e.g. intracranial haemorrhage or ischaemic stroke), or relative/absolute mortality to dialysis may be the cause.
The number of incident cases in our study was different from the report of Taiwan Society of Nephrology (TSN)
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. The reasons were different definitions of ESRD on maintenance dialysis and inclusion criteria. In the report of TSN 11 , ESRD on maintenance dialysis was defined as received maintenance dialysis therapy for > 1 month. However, we used the definition of maintenance dialysis for more than 90 days. In addition, only adult patients (age ≥18 yr) on pure HD were included in our study. The TSN report included all incident cases, including HD, PD and switched type of dialysis.
In our study, 11.5 per cent of the ESRD patients had PS at the initiation of HD. The proportion of PS in dialysis population beyond the factor of age reflects the health status and the co-morbid conditions as cardiovascular disease. Inrig et al 26 reported that only 2.6 per cent of dialysis patients with PS had a lower prevalence of co-morbid disease with a mean age at onset of ESRD of 47 years, and 35.5 per cent had DM co-morbidity. From the result of HEMO study 27 , 19.5 per cent of HD patients had a clinical diagnosis of PS at baseline, in which age, presence of any cardiac disease and DM were significantly associated. This finding is similar to our results. In our nation-wide database, 6.2 per cent of aged 18-54 and 14.3 per cent of aged 55 yr had PS, and had co-morbidity with DM (72.9%), HTN (90.5%), HF (24.0%), CAD (35.4%) and PVD (5.4%), which were all associated with cardiovascular disease. Taken together, it is reasonable to speculate that age and co-morbidity are relevant to mortality in dialysis patients with PS.
Many studies have demonstrated that stroke survivors have a higher mortality risk than individuals in the general population [28] [29] [30] . However, little is known about the long-term prognosis among stroke survivors on dialysis. In the present study, the 1-year survival rates were 92.9 and 96.0 per cent in patients with and without PS, respectively, which were higher than the report of TSN (85.1%)
. This may be due to different inclusion criteria and definition for ESRD on maintenance dialysis. The 5-year survival rate among patients without PS was 68.4 per cent, which was higher than the report of TSN (53.7%) 11 . In contrast, the 5-year survival rate among patient with PS was 47.3 per cent, which was lower than the TSN report (53.7%)
. These findings suggested that the survival curve after PS had a deteriorated long-term prognosis than without PS. This time-dependent poor outcome is the result of CAD co-morbidity, systemic vascular disease as stroke or PVD, ageing factor, metabolic derangement, or secondary infection before and during dialysis 31 .
Our findings indicated that all patients with PS had an increased risk of mortality. Petty et al 32 reported that CAD (particularly in younger patients) and HF were the most important predictors of mortality in patients with cerebral infarction. Taken together, we hypothesize that beyond age, vascular origin is the most important factor related to the risk of mortality in patients on dialysis. Further studies are warranted to investigate the predictors of mortality among stroke survivors.
There were several limitations to this study. First, the diagnosis of co-morbidities relied on the claim data and ICD-9-CM diagnosis codes, which might have resulted in potential disease misclassification
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. Second, co-morbidities were assessed on the basis of a simple classification (present/ absent) that did not take into account the disease severity. Third, our study lacked data on duration and treatment regimens of diseases, biochemical data and socio-economic characteristics, which may have some influences in mortality. These should be considered as confounders or modifiers in future analysis. Finally, using the definition of ESRD on maintenance dialysis as starting dialysis for more than 90 days might be missing some early mortality within 90 days after initiation of dialysis.
In conclusion, based on nearly a 10-year period of longitudinal cohort analysis, our results showed that PS was an important predictor for all-cause mortality and poor long-term outcomes in patients on maintenance HD. Age was a decisive factor on outcomes, and the older patients had a higher cumulative mortality rate. Awareness of the relationship between stroke survivor and mortality is essential to dialysis patients especially in those with a prior history of stroke.
